The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate
Drug Metabolism and Disposition · 2023
DOI: 10.1124/dmd.123.001353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2023. Verfasst von Udomsak Udomnilobol und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences (U.U., S.J.) and Chulalongkorn University Drug Discovery and Drug Devel…. Hauptthemen laut MEDLINE: Dabigatran, Prodrugs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences (U.U., S.J.) and Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) (U.U., T.P.), Chulalongkorn Universi…
ORCID-Profile: Udomsak Udomnilobol, Suree Jianmongkol
Zitieren
APA
Udomnilobol, U., Jianmongkol, S., & Prueksaritanont, T. (2023). The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.123.001353
Vancouver
Udomnilobol U, Jianmongkol S, Prueksaritanont T. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate. Drug Metabolism and Disposition. 2023. doi:10.1124/dmd.123.001353
BibTeX
@article{Udomnilobol2023,
author = {Udomnilobol, Udomsak and Jianmongkol, Suree and Prueksaritanont, Thomayant},
title = {The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate},
journal = {Drug Metabolism and Disposition},
year = {2023},
doi = {10.1124/dmd.123.001353}
}
EUVIMED